JAK/HDAC-IN-2
CAT:
804-HY-149283
Size:
Inquire
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
JAK/HDAC-IN-2
- CAS Number: 3029138-43-7
- UNSPSC Description: JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers[1].
- Target Antigen: Apoptosis; HDAC; JAK
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/jak-hdac-in-2.html
- Solubility: 10 mM in DMSO
- Smiles: CC(NS(C1=CC(NC2=NC(NC3=CC=C(C=C3)OCCCCCCC(NO)=O)=NC=C2C)=CC=C1)(=O)=O)(C)C
- Molecular Weight: 570.70
- References & Citations: [1]Qianqian Qiu, et al. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers. J Med Chem. 2023 Apr 27;66(8):5753-5773.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported